Volume 3.41 | Oct 18

Hematopoiesis News 2.41, October 18, 2011
     In this issue: Publications | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Hematopoiesis News on Twitter
TOP STORY
TNF-α/Fas-RIP-1-Induced Cell Death Signaling Separates Murine Hematopoietic Stem Cells/Progenitors into Two Distinct Populations
Investigators studied the effects of TNF-α and Fas-induced death signaling in hematopoietic stem and progenitor cells by examining their contributions to the development of bone marrow failure syndromes in Tak1-knockout mice. [Blood] Abstract

ON164-STEMSOFT_645x110
PUBLICATIONS (Ranked by Impact Factor of the Journal)
LABORATORY RESEARCH

Targeting the SH2-Kinase Interface in Bcr-Abl Inhibits Leukemogenesis
Here, scientists show that an intramolecular interaction between the SH2 and kinase domains in Bcr-Abl is both necessary and sufficient for high catalytic activity of the enzyme. [Cell] Abstract


Correction of Sickle Cell Disease in Adult Mice by Interference with Fetal Hemoglobin Silencing
Here, researchers show that the repressor BCL11A is required in vivo for silencing of γ-globin expression in adult animals, yet dispensable for red cell production. [Science] Abstract | Press Release

Somatic Mutations in the Transcriptional Corepressor Gene BCORL1 in Adult Acute Myelogenous Leukemia
Here scientists report the discovery of novel somatic mutations in the transcriptional corepressor gene BCORL1 that is located on the X-chromosome. [Blood] Abstract

Galectin-3 Induced by Leukemia Microenvironment Promotes Drug Resistance and Bone Marrow Lodgment in Chronic Myelogenous Leukemia
In this study, researchers investigated the molecular mechanisms for bone marrow (BM) microenvironment-mediated drug resistance and BM lodgment in chronic myelogenous leukemia. [Proc Natl Acad Sci USA] Abstract


Enrichment of Functionally Distinct Mouse Hematopoietic Progenitor Cell Populations Using CD62L
The details of the bifurcation of the lymphoid and myeloid lineages following commitment by multipotent progenitor cells remain a topic of controversy. Investigators report that the surface glycoprotein CD62L can be characterized as a novel marker of this and other stages of early hematopoietic differentiation. [J Immunol] Abstract


Combined Preconditioning and In Vivo Chemoselection with 6-Thioguanine Alone Achieves Highly Efficient Reconstitution of Normal Hematopoiesis with HPRT Deficient Bone Marrow
Here scientists have developed a novel and highly efficient strategy employing 6-thioguanine as a single agent for both conditioning and in vivo chemoselection of hypoxanthine-guanine phosphoribosyltransferase (HPRT)-deficient HSC. [Exp Hematol] Abstract


CLINICAL RESEARCH

Fludarabine Plus Alemtuzumab Versus Fludarabine Alone in Patients with Previously Treated Chronic Lymphocytic Leukemia: A Randomized Phase III Trial
Researchers compared the efficacy and safety of the combination of fludarabine and alemtuzumab with fludarabine monotherapy in previously treated patients with relapsed or refractory chronic lymphocytic leukemia. [Lancet Oncol] Abstract | Press Release

Front-Line Therapy with Second-Generation Tyrosine Kinase Inhibitors in Patients with Early Chronic Phase Chronic Myeloid Leukemia: What Is the Optimal Response?
One hundred sixty-seven patients with newly diagnosed chronic myelogenous leukemia in chronic phase were treated with second-generation tyrosine kinase inhibitors in phase II trials (nilotinib, 81; dasatinib, 86). [J Clin Oncol] Abstract


Multi-Institutional Phase II Clinical and Pharmacogenomic Trial of Tipifarnib Plus Etoposide for Elderly Adults with Newly Diagnosed Acute Myelogenous Leukemia
Investigators selected 2 comparable dose levels of tipifarnib plus etoposide for a randomized Phase II trial in 84 adults (age 70-90, median 76) who were not candidates for conventional chemotherapy. [Blood] Abstract


ON150-CASImmunomodulation_645x110a
INDUSTRY NEWS
Micromet Obtains FDA Feedback on Registration Strategy for Blinatumomab in Relapsed/Refractory ALL
Micromet, Inc. outlined a clinical development plan intended to support U.S. registration of its lead product candidate blinatumomab in patients with B-precursor relapsed/refractory acute lymphoblastic leukemia (ALL). [Micromet, Inc.] Press Release


Athersys Confirms Completion of Patient Enrollment for Its Phase I Study of MultiStem® for Hematopoietic Stem Cell Transplant Support
Athersys, Inc. announced that it has completed patient enrollment of the repeat dose arm of its clinical study involving administration of MultiStem® to patients being treated for leukemia or other blood born cancers. [Athersys, Inc.] Press Release


Cyclacel Announces Data Safety Monitoring Board Recommendation to Continue the SEAMLESS Phase III Trial of Sapacitabine
Cyclacel Pharmaceuticals, Inc. announced that the independent Data Safety Monitoring Board of SEAMLESS, the Phase III, randomized, registration-directed study of sapacitabine in elderly patients with acute myeloid leukemia, recommended that the study should enter the randomized stage as planned. [Cyclacel Pharmaceuticals, Inc.] Press Release
POLICY NEWS
National Institutes of Health (United States)

Food and Drug Administration (United States)
 
Center for Biologics Evaluation and Research (United States)
 
European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
EVENTS
NEW National Conference on Biopharmaceuticals & Healthcare
November 4-5, 2011
Bangalore, India

NEW AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics: Discovery, Biology, and Clinical Applications
November 12-16, 2011
San Francisco, United States

Visit our events page to see a complete list of events in the hematopoietic community
JOB OPPORTUNITIES

Lab Technologist – Tissue Culture (STEMCELL Technologies)

Research and Development Technologist, hPSC Media (STEMCELL Technologies)

Scientist (iPSC) (STEMCELL Technologies)

Contract Assay Service Technologist (STEMCELL Technologies)

Lab Technologist – Pluripotent Stem Cells (STEMCELL Technologies)

Quality Control Technologist – Cell Separation (STEMCELL Technologies)

Scientist – Pluripotent Stem Cells (STEMCELL Technologies)

Postdoctoral Position – Regulation of Hematopoiesis by Extrinsic Regulators (Stem Cell Center Lund University)

Postdoctoral Fellow – Hematopoietic Stem Cells (City of Hope)

Postdoctoral Fellows – Blood Systems Research Institute (University of California, San Francisco)

Recruit Top Talent

Reach more than 11,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Jobs are categorized regionally: United States, Canada, Europe,
Asia Pacific

Visit here to post your career opportunities.

Have we missed an important article or publication in Hematopoiesis News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Hematopoiesis Cell News: Archives | Events | Contact Us